Welcome to our dedicated page for Akebia Therapeut SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akebia Therapeutics, Inc. (Nasdaq: AKBA) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering investors structured access to its official communications. As a biopharmaceutical company focused on kidney disease, Akebia uses filings such as Forms 8-K, 10-K, and 10-Q to report material agreements, financial performance, and key clinical and regulatory developments related to products like Vafseo (vadadustat) and Auryxia (ferric citrate), as well as its rare kidney disease pipeline.
Recent 8-K filings illustrate the type of information investors can expect. One filing describes an amendment to Akebia’s License Agreement with MEDICE Arzneimittel Putter GmbH & Co. KG, under which Akebia supplies vadadustat drug substance and Medice has rights to manufacture Vafseo tablets for Europe and certain other countries, with resulting know-how and patent rights owned by Akebia. Other 8-Ks furnish quarterly financial results, highlight business updates such as Vafseo commercialization metrics, and disclose regulatory decisions, including Akebia’s announcement that it does not plan to initiate the VALOR trial and does not expect to pursue a broad label for Vafseo in CKD patients not on dialysis.
Through this page, users can review annual reports on Form 10-K for comprehensive discussions of risk factors, product portfolios, and strategy; quarterly reports on Form 10-Q for interim financial and operational updates; and current reports on Form 8-K for material events. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers. Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight material changes, and help readers quickly understand how new disclosures may relate to Akebia’s kidney disease programs and overall business.
Akebia Therapeutics director Philip J. Vickers received a grant of stock options covering 214,400 shares of common stock. The options have an exercise price of $1.41 per share and expire on April 1, 2036. This is a compensation award, not an open-market purchase.
According to the company’s 2023 Plan and its Fifth Amended and Restated Non-Employee Director Compensation Program, one third of the options will vest on the first anniversary of the grant date. The remaining two thirds will vest in equal installments on the first day of each calendar quarter thereafter, if he continues serving the company.
Akebia Therapeutics, Inc. has filed an initial insider report identifying Philip J. Vickers as a reporting person in his role as a director. The filing data show no reported transactions, no derivative positions, and no holding entries associated with him in this Form 3.
Akebia Therapeutics announced a Board change, with Steven C. Gilman, Ph.D. resigning as a Class I director effective April 1, 2026, stating his resignation is not due to any disagreement with the company. The Board elected Philip J. Vickers, Ph.D. as a new Class I director effective the same date, with an initial term running through the 2027 annual meeting of stockholders.
Dr. Vickers will serve on the Compensation Committee and the Research & Development Committee and will be compensated under Akebia’s non-employee director program. He is eligible for annual cash retainers of $50,000 for Board service, $7,500 for Compensation Committee membership, and $5,000 for Research & Development Committee membership, plus future annual equity grants of options to purchase 53,600 shares and 35,700 restricted stock units starting at the 2027 annual meeting. As a new director, he received a one-time grant of 214,400 stock options on April 1, 2026 at an exercise price of $1.41 per share.
Akebia Therapeutics Inc filing an Amendment No. 1 to a Schedule 13G/A reporting that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class. The filing notes an internal Vanguard realignment effective January 12, 2026 and is signed on 03/26/2026.
Akebia Therapeutics CEO and President John P. Butler reported an open‑market purchase of 69,270 shares of common stock on March 4, 2026 at an average price of $1.25 per share, with individual trades between $1.23 and $1.28. Following this transaction, his directly held stake rose to 3,367,064 shares of common stock. The filing also notes 159,928 shares held indirectly through the Dorothy Butler Revocable Trust November 20, 2007. A footnote explains that this purchase was matchable under Section 16(b) against a prior sale of 341,305 shares at $1.39 on February 2, 2026, and Butler paid $9,664.60 to Akebia, representing the full short‑swing profit.
Akebia Therapeutics is a kidney-focused biopharmaceutical company with two commercial oral drugs and a growing pipeline. Vafseo (vadadustat), the only oral HIF-based treatment for anemia due to chronic kidney disease in U.S. dialysis patients, launched in January 2025 into a roughly $1 billion market and already has prescribing access for about 290,000 dialysis patients.
Auryxia (ferric citrate) treats hyperphosphatemia in dialysis patients and iron deficiency anemia in non‑dialysis CKD, but lost U.S. exclusivity in March 2025, with broader generic competition expected in 2026 that could pressure revenue. Akebia is advancing mid‑stage rare kidney disease programs praliciguat (Phase 2 in FSGS) and AKB‑097 (planned Phase 2 basket in C3G, IgAN and lupus nephritis), plus early HIF candidates AKB‑9090 for cardiac surgery–related acute kidney injury and potential ARDS use, and AKB‑10108 for retinopathy of prematurity. The company highlights significant ongoing losses, the need for additional financing, heavy dependence on Auryxia and Vafseo, and extensive regulatory, clinical, manufacturing and intellectual‑property risks.
Akebia Therapeutics reported higher fourth quarter and full-year 2025 results, driven mainly by Vafseo and Auryxia. Total revenue rose to $57.6 million in Q4 2025 from $46.5 million a year earlier and to $236.2 million for 2025 from $160.2 million in 2024. Vafseo net product revenue reached $45.8 million in its first full year, while Auryxia generated $181.5 million. Net loss narrowed sharply to $5.3 million for 2025 from $69.4 million in 2024, helped by higher sales and lower amortization charges. Cash and cash equivalents increased to $184.8 million at December 31, 2025, from $51.9 million a year earlier, and the company expects current cash and operating cash flow to fund its plan for at least two years. Management anticipates significant Vafseo revenue growth in 2026 but expects Auryxia revenue to decline as generic competition expands, while advancing multiple Phase 2 and Phase 3 trials in rare kidney diseases.
State Street Corporation has disclosed a passive ownership stake in Akebia Therapeutics Inc. common stock on a Schedule 13G. As of 12/31/2025, State Street reported beneficial ownership of 13,687,561 shares, representing 5.2% of Akebia’s outstanding common stock.
State Street reported no sole voting or dispositive power over these shares, but shared voting power over 13,169,907 shares and shared dispositive power over 13,687,561 shares. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of Akebia.
Akebia Therapeutics SVP and Chief Accounting Officer Richard C. Malabre reported two stock sales of Akebia Therapeutics, Inc. common shares. On February 2, 2026, he sold 36,142 shares at $1.39 per share and 13,382 shares at $1.39 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025, and were made automatically by the company to cover tax withholding obligations related to vesting of restricted stock units granted on January 31, 2024 and January 31, 2025. After these transactions, Malabre directly owned 299,390 common shares of Akebia.
Akebia Therapeutics chief commercial officer Nicholas Grund reported sales of company stock. On February 2, 2026, he sold 53,585 shares of Akebia common stock at $1.39 per share, followed by an additional sale of 31,244 shares at the same price.
According to the footnotes, one sale was made under a pre-arranged Rule 10b5-1 trading plan, and other sales were made automatically by Akebia to cover tax withholding tied to the vesting and settlement of restricted stock units granted in January 2024 and January 2025. After these transactions, Grund directly owned 561,750 shares of Akebia common stock.